1. Home
  2. PGRE vs WVE Comparison

PGRE vs WVE Comparison

Compare PGRE & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGRE
  • WVE
  • Stock Information
  • Founded
  • PGRE 1978
  • WVE 2012
  • Country
  • PGRE United States
  • WVE Singapore
  • Employees
  • PGRE N/A
  • WVE N/A
  • Industry
  • PGRE Real Estate Investment Trusts
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • PGRE Real Estate
  • WVE Health Care
  • Exchange
  • PGRE Nasdaq
  • WVE Nasdaq
  • Market Cap
  • PGRE 953.6M
  • WVE 939.3M
  • IPO Year
  • PGRE 2014
  • WVE 2015
  • Fundamental
  • Price
  • PGRE $4.56
  • WVE $6.59
  • Analyst Decision
  • PGRE Hold
  • WVE Strong Buy
  • Analyst Count
  • PGRE 3
  • WVE 11
  • Target Price
  • PGRE $4.33
  • WVE $20.91
  • AVG Volume (30 Days)
  • PGRE 2.6M
  • WVE 1.7M
  • Earning Date
  • PGRE 04-30-2025
  • WVE 05-08-2025
  • Dividend Yield
  • PGRE 0.77%
  • WVE N/A
  • EPS Growth
  • PGRE N/A
  • WVE N/A
  • EPS
  • PGRE N/A
  • WVE N/A
  • Revenue
  • PGRE $711,729,000.00
  • WVE $104,939,000.00
  • Revenue This Year
  • PGRE $1.17
  • WVE N/A
  • Revenue Next Year
  • PGRE N/A
  • WVE N/A
  • P/E Ratio
  • PGRE N/A
  • WVE N/A
  • Revenue Growth
  • PGRE 49.28
  • WVE N/A
  • 52 Week Low
  • PGRE $3.75
  • WVE $4.25
  • 52 Week High
  • PGRE $5.47
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • PGRE 56.45
  • WVE 42.81
  • Support Level
  • PGRE $4.50
  • WVE $5.62
  • Resistance Level
  • PGRE $4.79
  • WVE $6.73
  • Average True Range (ATR)
  • PGRE 0.16
  • WVE 0.61
  • MACD
  • PGRE 0.03
  • WVE 0.07
  • Stochastic Oscillator
  • PGRE 66.19
  • WVE 34.84

About PGRE Paramount Group Inc.

Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: